跳至主要内容
临床试验/NCT00822991
NCT00822991Unknown不适用

Sonazoid Enhanced Liver Cancer Trial for Early Detection

Kindai University2 个研究点 分布在 1 个国家目标入组 760 人开始时间: 2009年1月最近更新:
适应症

试验速览

阶段
不适用
入组人数
760
试验地点
2
主要终点
Size of HCC which is detected first

研究概览

简要总结

The aim of this study is to prove usefulness of contrast-enhanced ultrasound (CE-US) using Sonazoid (TM) in the early detection of HCC as compared with conventional B-mode ultrasound (B-mode US) for hepatitis virus related cirrhosis, who are defined as super high-risk patients for hepatocarcinogenesis,Furthermore, to analyze whether early detection of HCC by CE-US has a survival benefit than that by B-mode US.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age over 20
  • HBV or HCV related liver cirrhosis
  • No history of HCC
  • Diagnosed as liver cirrhosis histologically or clinically Histologically confirmed by liver biopsy Confirmed by formula of diagnosing cirrhosis Radiological finding Finding of portal hypertension Platelet<130,000
  • Inpatient or outpatient
  • Patients who signed a written informed consent form

排除标准

  • History of hypersensitivity to egg yolk
  • Pregnant or lactating women and women who may be pregnant
  • Severe liver dysfunction(AST, ALT,or BIL level >10ULN
  • Associated with HCC
  • Patients receiving interferon
  • Age under 20
  • Judged by investigator not to be appropriate for inclusion in this study

结局指标

主要结局

Size of HCC which is detected first

时间窗: 10 years

次要结局

  • Time to detection of HCC(10 years)
  • The improvement of prognosis of patients who are diagnosed in this study(10 years)

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验